These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 20068087

  • 1. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?
    Finn RS.
    Clin Cancer Res; 2010 Jan 15; 16(2):390-7. PubMed ID: 20068087
    [Abstract] [Full Text] [Related]

  • 2. Molecularly targeted therapy in hepatocellular carcinoma.
    Huynh H.
    Biochem Pharmacol; 2010 Sep 01; 80(5):550-60. PubMed ID: 20371362
    [Abstract] [Full Text] [Related]

  • 3. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
    Zhu AX.
    Expert Opin Investig Drugs; 2010 May 01; 19(5):663-72. PubMed ID: 20367287
    [Abstract] [Full Text] [Related]

  • 4. Novel inhibitors in development for hepatocellular carcinoma.
    Wörns MA, Galle PR.
    Expert Opin Investig Drugs; 2010 May 01; 19(5):615-29. PubMed ID: 20374038
    [Abstract] [Full Text] [Related]

  • 5. The present and the future landscape of treatment of advanced hepatocellular carcinoma.
    Rimassa L, Santoro A.
    Dig Liver Dis; 2010 Jul 01; 42 Suppl 3():S273-80. PubMed ID: 20547314
    [Abstract] [Full Text] [Related]

  • 6. Targeted therapy of hepatocellular cancer.
    Wysocki PJ.
    Expert Opin Investig Drugs; 2010 Feb 01; 19(2):265-74. PubMed ID: 20074016
    [Abstract] [Full Text] [Related]

  • 7. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB.
    J Clin Oncol; 2006 Sep 10; 24(26):4293-300. PubMed ID: 16908937
    [Abstract] [Full Text] [Related]

  • 8. Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.
    Kim HY, Park JW.
    Dig Dis; 2011 Sep 10; 29(3):303-9. PubMed ID: 21829021
    [Abstract] [Full Text] [Related]

  • 9. [Hepatocellular carcinoma].
    Kondo S, Ueno H, Morizane C, Okusaka T.
    Gan To Kagaku Ryoho; 2010 Jul 10; 37(7):1219-23. PubMed ID: 20647702
    [Abstract] [Full Text] [Related]

  • 10. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma.
    Frau M, Biasi F, Feo F, Pascale RM.
    Mol Aspects Med; 2010 Apr 10; 31(2):179-93. PubMed ID: 20176048
    [Abstract] [Full Text] [Related]

  • 11. Systemic treatment of hepatocellular carcinoma: dawn of a new era?
    Zhu AX.
    Ann Surg Oncol; 2010 May 10; 17(5):1247-56. PubMed ID: 20405329
    [Abstract] [Full Text] [Related]

  • 12. Systemic treatment in hepatocellular carcinoma; 'A small step for man...'.
    Witjes CD, Verhoef C, Verheul HM, Eskens FA.
    Neth J Med; 2009 Mar 10; 67(3):86-90. PubMed ID: 19307678
    [Abstract] [Full Text] [Related]

  • 13. Systemic therapies in hepatocellular carcinoma.
    Wörns MA, Weinmann A, Schuchmann M, Galle PR.
    Dig Dis; 2009 Mar 10; 27(2):175-88. PubMed ID: 19546557
    [Abstract] [Full Text] [Related]

  • 14. Tyrosine kinase inhibitors to treat liver cancer.
    Huynh H.
    Expert Opin Emerg Drugs; 2010 Mar 10; 15(1):13-26. PubMed ID: 20128706
    [Abstract] [Full Text] [Related]

  • 15. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?
    Lencioni R, Chen XP, Dagher L, Venook AP.
    Oncologist; 2010 Mar 10; 15 Suppl 4():42-52. PubMed ID: 21115580
    [Abstract] [Full Text] [Related]

  • 16. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
    Chaparro M, González Moreno L, Trapero-Marugán M, Medina J, Moreno-Otero R.
    Aliment Pharmacol Ther; 2008 Dec 01; 28(11-12):1269-77. PubMed ID: 18808443
    [Abstract] [Full Text] [Related]

  • 17. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
    Zhang T, Ding X, Wei D, Cheng P, Su X, Liu H, Wang D, Gao H.
    Anticancer Drugs; 2010 Mar 01; 21(3):326-32. PubMed ID: 20016366
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy.
    Lencioni R.
    Crit Rev Oncol Hematol; 2012 Aug 01; 83(2):216-24. PubMed ID: 22142656
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Düber C, Otto G, Galle PR.
    J Clin Gastroenterol; 2009 Aug 01; 43(5):489-95. PubMed ID: 19247201
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.